Brandywine Global Investment Management’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2024
Q4 | – | Sell |
-392,118
| Closed | -$8.09M | – | 595 |
|
2024
Q3 | $8.09M | Sell |
392,118
-43,513
| -10% | -$898K | 0.05% | 308 |
|
2024
Q2 | $6.75M | Buy |
435,631
+64,248
| +17% | +$995K | 0.05% | 339 |
|
2024
Q1 | $5.92M | Buy |
371,383
+192,853
| +108% | +$3.07M | 0.04% | 379 |
|
2023
Q4 | $3M | Sell |
178,530
-38,679
| -18% | -$650K | 0.02% | 489 |
|
2023
Q3 | $2.54M | Buy |
217,209
+4,700
| +2% | +$54.9K | 0.02% | 508 |
|
2023
Q2 | $2.86M | Sell |
212,509
-1,000
| -0.5% | -$13.4K | 0.02% | 490 |
|
2023
Q1 | $3.54M | Hold |
213,509
| – | – | 0.03% | 465 |
|
2022
Q4 | $3.97M | Hold |
213,509
| – | – | 0.03% | 438 |
|
2022
Q3 | $2.74M | Sell |
213,509
-8,758
| -4% | -$112K | 0.03% | 476 |
|
2022
Q2 | $1.56M | Sell |
222,267
-32,400
| -13% | -$227K | 0.01% | 568 |
|
2022
Q1 | $2.11M | Hold |
254,667
| – | – | 0.02% | 535 |
|
2021
Q4 | $1.72M | Sell |
254,667
-96,975
| -28% | -$656K | 0.01% | 544 |
|
2021
Q3 | $1.86M | Buy |
351,642
+2,014
| +0.6% | +$10.7K | 0.01% | 534 |
|
2021
Q2 | $2.01M | Sell |
349,628
-4,259
| -1% | -$24.5K | 0.01% | 536 |
|
2021
Q1 | $1.63M | Sell |
353,887
-3,438
| -1% | -$15.8K | 0.01% | 541 |
|
2020
Q4 | $1.19M | Sell |
357,325
-92,355
| -21% | -$308K | 0.01% | 522 |
|
2020
Q3 | $1.34M | Buy |
449,680
+108,890
| +32% | +$324K | 0.01% | 491 |
|
2020
Q2 | $1.58M | Buy |
340,790
+3,228
| +1% | +$14.9K | 0.02% | 477 |
|
2020
Q1 | $1.3M | Buy |
337,562
+2,150
| +0.6% | +$8.28K | 0.02% | 493 |
|
2019
Q4 | $1.27M | Buy |
335,412
+53,735
| +19% | +$203K | 0.01% | 557 |
|
2019
Q3 | $1.5M | Sell |
281,677
-67,395
| -19% | -$358K | 0.01% | 555 |
|
2019
Q2 | $1.34M | Buy |
349,072
+135,597
| +64% | +$521K | 0.01% | 568 |
|
2019
Q1 | $1.09M | Buy |
+213,475
| New | +$1.09M | 0.01% | 539 |
|